

Optimizing Care



*Expanding Treatment Free Remission (TFR)
Access in Low- and Middle-Income Countries (LMICs) for
People Living With Chronic Myeloid Leukemia (CML)*

Approximately 5 million people
live with CML worldwide,
many in low-resource countries.





For CML patients, regular monitoring is important to know how well the treatment is working. For people whose results stay very good over several years, doctors may consider whether it's safe to stop treatment under close medical supervision.


Although TFR is common in high-income countries, it remains difficult to implement in low- and middle-income countries due to limited access to:

This is called treatment free remission (TFR).

TFR can improve quality of life by reducing treatment-related side effects, such as:



Patients who want to attempt TFR need to discuss with their physicians if they qualify; eligibility criteria in Max programs include:



The patient journey when doing TFR requires holistic support





Since 2021,
The Max Foundation
has supported CML patients

to attempt TFR by
providing financial assistance
and access to molecular
diagnostics, now in 8 countries.



Thanks to our collaboration with Cepheid and local labs, partnering medical institutions can monitor patients in our TFR program.



Frequent molecular testing is essential to ensure the safety of patients.

“

I had no idea what this discipline of being adherent to my treatment would lead me to, and that was to be part of this new TFR program in Honduras. When my physician told me about the TFR program I felt motivated and happy, my dream came true, to stop taking the medication. I had been taking it for 18 years.



Mario in Honduras

Investments in *health system strengthening* and *patient support* are essential for successful TFR implementation in resource-limited settings.

Learn More About Creating
Access to Innovative Solutions

